MannKind Corporation (MNKD) UBS Global Biopharma Conference 2026 November 17, 2026 6:20 AM EST.

Michael Castagna - CEO & Director.

Ashwani Verma - UBS Investment Bank, Research Division.

Ashwani VermaUBS Investment Bank, Research Division.

Recent findings suggest that good day, everybody. Welcome back to UBS Biopharma Conference in London and really excited to have MannKind here. My name is Ash Verma. And with me, I have Michael Castagna, who is the CEO of the organization. Thanks, Mike, for joining us.

Recent findings suggest that thank you for having us. Appreciate it.

Ashwani VermaUBS Investment Bank, Research Division.

Sources indicate that great. So a lot of people are kind of familiar with your story as well, but just maybe if you can give a hit a couple of key highlights of some of the recent updates coming out of third quarter earnings, and then we can take it from there.

Sure. For those who don't know the firm, it's originally based on a DPI platform of inhalation technologies. We've evolved with purchasing an injectable product called FUROSCIX. So that's been a big highlight here for Q3. The company is really broken down into 3 different businesses as you think about it. We have a royalty manufacturing stream with a partnership with United. We have a diabetes franchise with the history of Afrezza, and we got the FUROSCIX in the commercial side. And then you got the third arm is the pipeline, which is around the inhaled nintedanib. So it's exciting.

Ashwani VermaUBS Investment Bank, Research Division.

Awesome. So maybe just if I talk about FUROSCIX, what made this brand as a strategic fit for you and some of the early launch metrics that you're looking at, what drives your conviction that there is more long-term growth.

→ Read original article